Join
Live feed
·
PRReleasevia Quantisnow
argenx SE logo

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

ByQuantisnow·Wall Street's wire, on your screen.
ARGX· argenx SE
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARGX (argenx SE) and more on Quantisnow.